News Sentiment

FATE sentiment intelligence

Fate Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.10 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+6.2% over one week, +50.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend active 50.5% over four weeks
Fair value 23.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 25
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 5
simplywall.st 5
Investing.com 4
GlobeNewswire 4
TradingView 4
Stocktwits 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 12
Analyst action 7
Regulatory and legal 6
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
GuruFocus Direct company coverage

BlackRock, Inc. Reduces Stake in Fate Therapeutics Inc

BlackRock, Inc. has significantly reduced its stake in Fate Therapeutics Inc by selling 7,874,330 shares at $2.70 per share, leaving them with 2,194,284 shares. This move suggests a strategic reevaluation of its investment in the biopharmaceutical company, which is currently cons

Tone
Negative 28/100
Event
Deals and strategy
Published
15 Jul 2026 00:45
Source
GuruFocus
ANCA Vasculitis News Direct company coverage

FDA approves clinical testing of CAR T-cell therapy for AAV, other conditions

The FDA has approved the initiation of clinical testing for Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy, FT839, for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans a basket Phase 1/2 trial to evaluate FT839, which is designe

Tone
Positive 87/100
Event
Market update
Published
13 Jul 2026 22:40
Source
ANCA Vasculitis News
Moomoo Direct company coverage

Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11

Needham has reaffirmed its Hold rating on Fate Therapeutics (FATE.US) and set a target price of $3.11. This indicates that while the firm sees no immediate reason to sell, it also does not anticipate significant upward movement in the stock price in the near term.

Tone
Positive 61/100
Event
Analyst action
Published
10 Jul 2026 14:10
Source
Moomoo
MarketBeat Direct company coverage

Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE

This article provides an overview of Fate Therapeutics' (FATE) FDA-related milestones and regulatory updates for its drug candidates FT839, FT819, and FT522 in 2025 and 2026. It details recent FDA clearances, preclinical and clinical data presentations, and special designations l

Tone
Positive 75/100
Event
Regulatory and legal
Published
10 Jul 2026 03:40
Source
MarketBeat
GlobeNewswire Direct company coverage

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for FT839, an off-the-shelf CAR T-cell product candidate designed to co-target CD19 and CD38 for autoimmune diseases and hematological malignancies. The company plans to initiate a

Tone
Positive 94/100
Event
Regulatory and legal
Published
10 Jul 2026 03:10
Source
GlobeNewswire
Moomoo Direct company coverage

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

Fate Therapeutics (FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an engineered B-cell lymphoma 2 (BCL2) inhibitor for solid tumors and lymphomas. This clearance allows Fate to begin a Phase 1 study, initiating a milestone p

Tone
Positive 70/100
Event
Regulatory and legal
Published
09 Jul 2026 22:07
Source
Moomoo
marketscreener.com Direct company coverage

Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

Fate Therapeutics (NASDAQ:FATE) shares increased after the FDA cleared its Investigational New Drug (IND) application for FT839, an iPSC-derived CAR T-cell product candidate targeting MICA and MICB proteins for solid tumors. The company is a clinical-stage biopharmaceutical firm

Tone
Positive 71/100
Event
Regulatory and legal
Published
09 Jul 2026 19:07
Source
marketscreener.com
Stocktwits Direct company coverage

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials

Fate Therapeutics Inc (FATE) saw its stock jump 6% after the FDA approved its application to begin clinical trials for its cell therapy, FT839. This clearance allows the company to start an early-stage basket trial for multiple autoimmune diseases later in 2026. FT839 is designed

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 16:52
Source
Stocktwits
Stock Titan Direct company coverage

FDA clears Fate Therapeutics' FT839 for autoimmune trial push

Fate Therapeutics (NASDAQ: FATE) has received FDA clearance for its Investigational New Drug (IND) application for FT839, an off-the-shelf, dual-CAR T-cell product designed to target both CD19 and CD38. This clearance paves the way for a Phase 1/2 basket clinical trial, expected

Tone
Positive 74/100
Event
Regulatory and legal
Published
09 Jul 2026 12:11
Source
Stock Titan
AD HOC NEWS Direct company coverage

Fate Therapeutics looks to its pipeline as investors weigh long-term prospects

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for oncology and hematology. Its stock performance is largely influenced by clinical trial news and regulatory progress, rather than broad market trends, due to i

Tone
Positive 62/100
Event
Regulatory and legal
Published
07 Jul 2026 22:12
Source
AD HOC NEWS
Sahm Direct company coverage

Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54

Insiders at Fate Therapeutics (NASDAQ:FATE) have recently sold stock, with the President selling shares at a price below the current market value. Despite a recent 21% rise in the stock price, insider selling over the past year and relatively low insider ownership levels suggest

Tone
Negative 39/100
Event
Market update
Published
06 Jul 2026 15:09
Source
Sahm
GlobeNewswire Direct company coverage

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics announced preliminary clinical data from its FT819 off-the-shelf CAR T-cell product candidate for Systemic Sclerosis (SSc) will be presented at the ISSCR 2026 Annual Meeting. The data from the first four SSc patients showed encouraging clinical activity and a we

Tone
Positive 74/100
Event
Market update
Published
06 Jul 2026 12:11
Source
GlobeNewswire
Stock Titan Direct company coverage

Fate Therapeutics to show early FT819 data in systemic sclerosis

Fate Therapeutics (NASDAQ:FATE) will present preliminary Phase 1 clinical data for its off-the-shelf CAR T-cell candidate FT819 in systemic sclerosis (SSc) at the ISSCR 2026 Annual Meeting. Early data from four treatment-refractory patients showed all achieved rCRISS ≥25 and mean

Tone
Positive 64/100
Event
Market update
Published
06 Jul 2026 12:11
Source
Stock Titan
GlobeNewswire Direct company coverage

Fate Therapeutics to Present Preliminary Clinical Data of

Fate Therapeutics, Inc. announced that preliminary clinical data for its off-the-shelf CAR T-cell product candidate, FT819, will be presented at the ISSCR 2026 Annual Meeting. The data, focusing on the Systemic Sclerosis arm of its Phase 1 trial, shows favorable tolerability and

Tone
Positive 75/100
Event
Market update
Published
06 Jul 2026 12:10
Source
GlobeNewswire
Stock Titan Direct company coverage

Fate Therapeutics lines up four investor conferences in Q3

Fate Therapeutics (NASDAQ:FATE) announced its management will participate in four investor conferences during the third quarter of 2026, including events hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright. These participations aim to increase the comp

Tone
Positive 64/100
Event
Earnings
Published
01 Jul 2026 20:11
Source
Stock Titan
The Manila Times Direct company coverage

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in the third quarter of 2026. Management will attend the Leerink Partners Therapeutics Forum, Wells Fargo 21st Annual Healthcare Conference, 12th Annual Cant

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 20:11
Source
The Manila Times
TradingView Direct company coverage

FATE Stock Price and Chart — NASDAQ:FATE

This article provides an overview of Fate Therapeutics, Inc. (FATE) stock, including its current price, key financial statistics, and performance. It details the company's business in developing cellular immunotherapies for cancer and immune disorders, lists its founding members

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 12:40
Source
TradingView
www.marketscreener.com Direct company coverage

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index

Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 3000E Index. This announcement follows similar removals from the Russell 2000 Index and Russell 2000 Value Benchmark on the same day. The company, a clinical-stage biopharmaceutical firm, specializes in iPS

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 18:12
Source
www.marketscreener.com
StocksToTrade Direct company coverage

Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders

Fate Therapeutics Inc. (FATE) stock increased by 11.76% after releasing positive early Phase 1 data for its FT836 cancer treatment in KRAS wild-type metastatic colorectal cancer, showing meaningful tumor reductions without conditioning chemotherapy. The company's strategic profil

Tone
Positive 75/100
Event
Market update
Published
28 Jun 2026 12:09
Source
StocksToTrade
marketscreener.com Direct company coverage

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index

Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 2000 Dynamic Index. This news was published on June 28, 2026, at 08:53 pm EDT by S&P Capital IQ. The company is a clinical-stage biopharmaceutical firm focused on developing off-the-shelf, multiplexed-engin

Tone
Negative 40/100
Event
Market update
Published
28 Jun 2026 08:53
Source
marketscreener.com
Benzinga Direct company coverage

Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History

This page provides a comprehensive overview of Fate Therapeutics Inc (FATE) stock, including its current price, historical data, news, and key financial metrics. It details the company's financial performance, analyst ratings, valuation, and market statistics. FATE is a clinical-

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 23:12
Source
Benzinga
TradingView Direct company coverage

Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T)

This article provides financial actuals and estimates for Fate Therapeutics, Inc. (F6T) traded on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst forecasts for its stock price. The article also details

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 13:09
Source
TradingView
TradingKey Direct company coverage

Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Fate Therapeutics Inc (FATE), noting its current valuation score is 7.14, ranking 255 out of 387 in the Biotechnology & Medical Research industry. It gives the stock's current P/E ratio as -1.72, which is significantly below its rece

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:40
Source
TradingKey
TradingView Direct company coverage

Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T)

This article provides an overview of Fate Therapeutics, Inc. (F6T) listed on the Tradegate Exchange, including its financial actuals, analyst estimates, and frequently asked questions. It details various financial metrics such as earnings, revenue, net income, EBITDA, and future

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:40
Source
TradingView